Bristol-Myers Squibb and Exelixis Extend Two Research Collaborations

doi:10.3833/pdr.v2002i27.1017

Pharma Deals Review, Vol 2002, No 27 (2002)

Bristol-Myers Squibb and Exelixis Extend Two Research Collaborations

Business Review Editor

Abstract

Bristol-Myers Squibb (BMS) extended research alliance with Exelixis. BMS and Exelixis now plan to initiate small molecule cancer drug discovery programs around their selected targets.

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.